Clinical Research Directory

Inclusion Criteria: Participants who meet all the following criteria will be included in the study. Cohorts 1 and 2: 1. Willing to provide written informed consent or currently enrolled in an ongoing participating AATD patient registry that does not require reconsenting to participate in the study. 2. \>=18 years of age at enrollment in this study. 3. Participants with documented diagnosis of AATD, meeting the following criteria: 1. Cohort 1 (AATD-Pi\*ZZ genotype/phenotype). • Pi\*ZZ genotype as documented from rapid genetic assay, sequencing, or polymerase chain reaction (PCR), or Pi\*ZZ phenotype as documented from iso-electric focusing (IEF) electrophoresis. 2. Cohort 2 (AATD-Pi\*SZ genotype/phenotype with liver disease manifestation). * Pi\*SZ genotype as documented from rapid genetic assay, sequencing, or PCR, or Pi\*SZ phenotype as documented from IEF electrophoresis, and * Moderate-advanced or severe liver disease manifestation as defined by either liver biopsy or surrogate laboratory or imaging measures, as determined through: * Lab and imaging measures to define liver disease manifestation Exclusion Criteria: Participants who meet any following criteria will be excluded from the study. 1. Documented AATD genotype/phenotype other than Pi\*ZZ or Pi\*SZ. 2. History of liver transplant. 3. No results for either biopsies, magnetic resonance elastography (MRE), fibro scan (vibration controlled transient elastography \[VCTE\]), or Aspartate aminotransferase to platelet ratio index (APRI) in the 24 months prior to the index/enrollment date and has none of these tests ordered during the index period. 4. Participants who had previously been treated or in an active participation in an interventional trial studying liver or lung disease. 5. Treatment with liver directed AATD investigational therapy as part of a compassionate use request.